The recommended all oral capecitabine/cyclophosphamide combination regimen is well tolerated and active in MBC, and is being evaluated in a phase II study in anthracycline
The fixed-dose combination of capecitabine and cyclophosphamide is effective and well-tolerated in the management of patients with MBC who have been
Adjuvant Capecitabine in Combination With Docetaxel, Epirubicin, and Cyclophosphamide for Early Breast Cancer: The Randomized Clinical FinXX Trial |
Capecitabine and cyclophosphamide are orally administered and have preclinical synergy and non-overlapping toxicities
PURPOSE Few data are available regarding the influence of adjuvant capecitabine on long-term survival of patients with early breast cancer
The primary endpoint was overall
8,9,30-32 In the GEICAM/2003 Combination Treatment of Vinorelbine With Oral Cyclophosphamide or Capecitabine or Both Might Overcome Cross-resistance Against Eribulin in Advanced Breast Cancer Clin Breast Cancer
2022
1,2 Yet little is known about the efficacy of capecitabine as adjuvant treatment of early breast cancer
Materials and methodsPatients received capecitabine 828 mg/m2 twice daily with cyclophosphamide 33 mg/m2 twice daily, days 1–14 every 3 weeks
Methods: This phase II study assessed the safety and efficacy of metronomic oral chemotherapy with vinorelbine 40 mg orally 3 times a week
Capecitabine (Xeloda, X) and cyclophosphamide (C) can be given orally and they have synergistic effects with nonoverlapping toxicities in preclinical studies
This world’s first fixed-dose combination of capecitabine and cyclophosphamide is a testament to the long-standing commitment
As for AEs due to combining The combination of docetaxel and capecitabine is attractive because of their different mechanisms of action and largely nonoverlapping side effects, namely, myelotoxicity and cutaneous/mucosal toxicity, respectively
5,6 In the ICE trial, patients older than age 65 years with early-stage breast cancer were randomly assigned to capecitabine or placebo in addition to a bisphosphonate for adjuvant The rationale for this combination was based on the observation that preclinical models of cyclophosphamide up-regulated tumor thymidine phosphorylase and increased the activation of capecitabine
Fixed dose combination of capecitabine and cyclophosphamide in metastatic breast cancer: Results from THE ENCLOSE phase 2/3 randomized multicenter study